Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia - PubMed

Affiliations

• PMID: 22112743
• DOI: 10.1016/j.amjcard.2011.09.019

Randomized Controlled Trial

Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia

Masa-Aki Kawashiri et al. Am J Cardiol. 2012.

Abstract

Aggressive low-density lipoprotein (LDL) cholesterol-lowering therapy is important for high-risk patients. However, sparse data exist on the impact of combined aggressive LDL cholesterol-lowering therapy in familial hypercholesterolemia (FH), particularly on side effects to changes in plasma coenzyme Q10 and proprotein convertase subtilisin/kexin type 9 levels. We enrolled 17 Japanese patients with heterozygous FH (12 men, 63.9 ± 7.4 years old) with single LDL receptor gene mutations in a prospective open randomized study. Permitted maximum doses of rosuvastatin (20 mg/day), ezetimibe (10 mg/day), and granulated colestimide (3.62 g/day) were introduced sequentially. Serum levels of LDL cholesterol decreased significantly by -66.4% (p <0.001) and 44% of participants achieved LDL cholesterol levels <100 mg/dl. There were no serious side effects or abnormal laboratory data that would have required the protocol to have been terminated except for 1 patient with myalgia. Coadministration of ezetimibe and granulated colestimide further lowered serum LDL cholesterol more than rosuvastatin alone without changing plasma coenzyme Q10 and proprotein convertase subtilisin/kexin type 9 levels. In conclusion, adequate introduction of this aggressive cholesterol-lowering regimen can improve the lipid profile of FH.

Similar articles

• Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).

  Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, Jones-Burton C. Bays HE, et al. Am J Cardiol. 2011 Aug 15;108(4):523-30. doi: 10.1016/j.amjcard.2011.03.079. Epub 2011 May 17. Am J Cardiol. 2011. PMID: 21596364 Clinical Trial.

• Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.

  Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM. Catapano AL, et al. Curr Med Res Opin. 2006 Oct;22(10):2041-53. doi: 10.1185/030079906X132721. Curr Med Res Opin. 2006. PMID: 17022864 Clinical Trial.

• Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).

  Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E; EXPLORER Study Investigators. Ballantyne CM, et al. Am J Cardiol. 2007 Mar 1;99(5):673-80. doi: 10.1016/j.amjcard.2006.10.022. Epub 2007 Jan 4. Am J Cardiol. 2007. PMID: 17317370 Clinical Trial.

• Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.

  McKenney JM. McKenney JM. Am J Cardiol. 2005 Aug 22;96(4A):60E-66E. doi: 10.1016/j.amjcard.2005.06.007. Am J Cardiol. 2005. PMID: 16098846 Review.

• Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

  Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Nicholls SJ, et al. Am J Cardiol. 2010 Jan 1;105(1):69-76. doi: 10.1016/j.amjcard.2009.08.651. Am J Cardiol. 2010. PMID: 20102893 Review.

Cited by

• Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022.

  Harada-Shiba M, Arai H, Ohmura H, Okazaki H, Sugiyama D, Tada H, Dobashi K, Matsuki K, Minamino T, Yamashita S, Yokote K. Harada-Shiba M, et al. J Atheroscler Thromb. 2023 May 1;30(5):558-586. doi: 10.5551/jat.CR005. Epub 2023 Jan 21. J Atheroscler Thromb. 2023. PMID: 36682773 Free PMC article. No abstract available.

• Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis.

  Oh J, Lee CJ, Kim DI, Rhee MY, Lee BK, Ahn Y, Cho BR, Woo JT, Hur SH, Jeong JO, Jang Y, Lee SH. Oh J, et al. Clin Cardiol. 2017 Dec;40(12):1291-1296. doi: 10.1002/clc.22826. Epub 2017 Dec 14. Clin Cardiol. 2017. PMID: 29243274 Free PMC article.

• Current Treatment of Familial Hypercholesterolaemia.

  Lambert CT, Sandesara P, Isiadinso I, Gongora MC, Eapen D, Bhatia N, Baer JT, Sperling L. Lambert CT, et al. Eur Cardiol. 2014 Dec;9(2):76-81. doi: 10.15420/ecr.2014.9.2.76. Eur Cardiol. 2014. PMID: 30310490 Free PMC article. Review.

• Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects.

  Kawashiri MA, Hayashi K, Konno T, Fujino N, Ino H, Yamagishi M. Kawashiri MA, et al. Heart Vessels. 2014 Mar;29(2):129-41. doi: 10.1007/s00380-013-0391-5. Epub 2013 Aug 2. Heart Vessels. 2014. PMID: 23907713 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal